Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gerlach

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Neurology|April 12, 2022
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry StudyMarianna Vitkova, Ibrahima Diouf, Charles Malpas, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Neurology|April 12, 2022
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry StudyMarianna Vitkova, Ibrahima Diouf, Charles Malpas, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Pageof 6